Incorporation of lipolysis in monolayer permeability studies of lipid-based oral drug delivery systems.
Lipid-based drug delivery systems, a well-tolerated class of formulations, have been evaluated extensively to enhance the bioavailability of poorly soluble drugs. However, it has been difficult to predict the in vivo performance of lipid dosage forms based on conventional in vitro techniques such as cell monolayer permeability studies because of the complexity of the gastrointestinal processing of lipid formulations. In the current study, we explored the feasibility of coupling Caco-2 and Madin-Darby canine kidney monolayer permeability studies with lipolysis, a promising in vitro technique to evaluate lipid systems. A self-emulsifying lipid delivery system was formulated using a blend of oil (castor oil), surfactant (Labrasol® or PL497), and co-surfactant (lecithin). Formulations demonstrating high drug solubility and rapid self-emulsification were selected to study the effect of lipolysis on in vitro cell permeability. Lipolysis of the formulations was carried out using pancreatin as the digestive enzyme. All the digested formulations compromised monolayer integrity as indicated by lowered trans-epithelial electrical resistance (TEER) and enhanced Lucifer yellow (LY) permeability. Further, the changes in TEER value and LY permeability were attributable to the digestion products of the formulation rather than the individual lipid excipients, drug, digestion enzyme, or the digestion buffer. The digested formulations were fractionated into pellet, oily phase, and aqueous phase, and the effect of each of these on cell viability was examined. Interestingly, the aqueous phase, which is considered important for in vivo drug absorption, was responsible for cytotoxicity. Because lipid digestion products lead to disruption of cell monolayer, it may not be appropriate to combine lipolysis with cell monolayer permeability studies. Additional in vivo studies are needed to determine any potential side effects of the lipolysis products on the intestinal permeability barrier, which could determine the suitability of lipid-based systems for oral drug delivery.
['Sadhukha|Tanmoy|T|', 'Layek|Buddhadev|B|', 'Prabha|Swayam|S|']
D000166:Acridines D000284:Administration, Oral D000818:Animals D018938:Caco-2 Cells D002368:Castor Oil D002470:Cell Survival D004285:Dogs D016503:Drug Delivery Systems D005079:Excipients D006801:Humans D054709:Lecithins D008066:Lipolysis D061985:Madin Darby Canine Kidney Cells D010539:Permeability D013501:Surface-Active Agents D044005:Tetrahydroisoquinolines
Lipolysis Monolayer permeability Lipid formulation Trans-epithelial electrical resistance Intestinal absorption Lucifer yellow permeability